Evidence map›Paper›PMID 40950507›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Valvular Heart Disease Associations with Cardiac Biomarkers Using AI-guided Echocardiography: the RURAL Cohort Study.

Evangelia Alexopoulos, Joanna Walsh, Jesse Y Hsu, Michael J Blaha, Susan Cheng, Melissa A Daubert, Gary Dunn, Peter Durda, Ervin Ray Fox, Yngvil Thomas and 5 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Evangelia AlexopoulosDuke University School of Medicine, Duke University, Durham, NC, USA.
Joanna WalshPerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Jesse Y HsuPerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Michael J BlahaJohns Hopkins, Baltimore, MD, USA.
Susan ChengCedars Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-4977-036X
Melissa A DaubertDuke Clinical Research Institute and Department of Medicine, Duke University, Durham, NC, USA.
Gary DunnDuke Clinical Research Institute and Department of Medicine, Duke University, Durham, NC, USA.
Peter DurdaUniversity of Vermont, Burlington, VT, USA.
Ervin Ray FoxUniversity of Mississippi, University, MS, USA.
Yngvil ThomasGE Healthcare.
Edwin van den HeuvelEindhoven University of Technology, Eindhoven, the Netherlands.
Suzanne E JuddUniversity of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0001-7594-6587
Ramachandran S VasanUniversity of Texas School of Public Health and Health Sciences Center, San Antonio, TX, USA.
Pamela S DouglasDuke Clinical Research Institute and Department of Medicine, Duke University, Durham, NC, USA.
Gerald S BloomfieldDuke Clinical Research Institute and Department of Medicine, Duke University, Durham, NC, USA.

Funding

RURAL: Risk Underlying Rural Areas Longitudinal Cohort StudyU01HL146382 · NHLBI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI JUDD, SUZANNE E, RAMACHANDRAN, VASAN · 2019 to 2025
$42.5M
Epidemiologic Determinants of Cardiac Structure and Function in Rural Residents: RURAL ECHOR01HL157531 · NHLBI · DUKE UNIVERSITY · PI BLOOMFIELD, GERALD SAMUEL, DOUGLAS, PAMELA SUSAN · 2022 to 2025
$4.9M
NHLBI NIH HHS R01 HL157531NHLBI NIH HHS U01 HL146382
6 · The paper itself

Abstract

Background: Few studies have evaluated the prevalence or severity of mitral valve prolapse (MVP) and other valvular heart disease (VHD) in the rural US South, where strategies for early detection are crucial for risk stratification and prevention. Objectives: We assessed the prevalence of MVP and other VHD in a rural US South cohort and examined associations with cardiovascular disease (CVD) risk. We also evaluated relationships between MVP severity, high-sensitivity cardiac troponin T (hsTnT), and N-terminal pro-B-type natriuretic peptide (NTproBNP). Methods: We conducted a cross-sectional analysis from the Risk Underlying Rural Areas Longitudinal (RURAL) study. Logistic regression assessed associations between participant characteristics and MVP, other VHD, or both. Weighted models assessed odds for MVP and other VHD by 10-year CVD risk categories using the Predicting Risk of CVD Events (PREVENT) score. Among a subset, we evaluated associations between MVP severity and cardiac biomarkers. Results: Among 2,621 participants (68.7% women), MVP and other VHD were present in 1.9% and 11.2%, respectively. Compared to the low PREVENT risk group, odds of MVP were lower and odds of VHD were higher among borderline and intermediate/high groups. HsTnT was lower in MVP vs. non-MVP (0.64, 95% CI 0.58-0.71), without difference by severity of MVP. NTproBNP was higher in participants with severe MVP than non-MVP (2.05, 95% CI 1.49-2.83). Conclusions: MVP prevalence aligned with population-based epidemiologic studies. PREVENT risk category may differentiate individuals at higher risk for MVP and for other VHD. Future studies are needed to evaluate relationships between MVP/VHD status and clinical events.

Indexed as

biomarkersMitral valve prolapserural countiesvalvular heart disease

Identifiers

PMID40950507
PMCPMC12425031

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.